Henggliflozin
ApprovedSmall molecule
Henggliflozin is one of 24 small molecule programs targeting Type 2 Diabetes. It is currently in Approved.
2
Indications
2
Total Trials
2
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Henggliflozin
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Approved
NOVOLIN R
Novo NordiskPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes1 trial
Heart Failure Preserved Ejection Fraction1 trial
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
Not yet recruiting·TThe First Affiliated Hospital of Air Force Medicial University·Preclinical·NCT07687212·162 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Henggliflozin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details